A team of scientists from the United States has recently developed a formulation of toll-like receptor 9 (TLR9) agonist and aluminum hydroxide to increase the immunogenicity of spike receptor-binding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback